Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children

Article Abstract:

A study was conducted to assess the rate of progression of lipodystrophy and the associated metabolic disturbances over a 2-year period in children and to assess risk factors associated with lipodystrophy and metabolic disturbances. The observations indicate that puberty seems to be the time when children are most likely to develop lipodystrophy and metabolic complications, especially in children with severe underlying HIV infection.

Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
Complications and side effects, Risk factors, Antiviral agents, Antiretroviral agents, Lipodystrophy, Disease/Disorder overview

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children

Article Abstract:

A study that was carried out to assess whether the substitution to stavudine (d4T) with short term use of tenofovir (TDF) would result in decreased bone mineral content and bone mineral density accrual in HIV-infected children is discussed. It is observed that substitution to a TDF-containing antiretroviral regimen does not impair bone mineral accrual in children showing a good immunologic response to antiretroviral treatment.

Author: Mora, Stefano, Giacomet, Vania, Martelli, Laura, Merlo, Marzia, Sciannamblo, Mariateresa, Vigano, Alessandra
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
Usage, Bones, Bone density, Tenofovir

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Disease progression among HIV-infected children who receive perinatal zidovudine prophylaxis

Article Abstract:

A population-based cohort of children with perinatal HIV infection is used to examine the effect of perinatal zidovudine prophylaxis (PZP) on early disease progression among infants with breakthrough perinatal HIV infection. The analysis has suggested that HIV-infected children receiving PZP started antiretroviral therapy (ART) at an early age and has shown decreased HIV disease progression by the age of 3 years.

Author: Berk, David R.
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2007
United States, Development and progression, Children, Child health, Zidovudine, Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy, HIV infection in children, Pediatric HIV infections, Health aspects
Similar abstracts:
  • Abstracts: National surveillance for type 2 diabetes mellitus in Taiwanese children. Use of quarantine to prevent transmission of severe acute respiratory syndrome -- Taiwan, 2003
  • Abstracts: Prevalence of and risk factors for lifetime suicide attempts among Blacks in the United States. Violence-related behaviors among high school students-United States, 1991-2003
  • Abstracts: Nutrition and immune function. Designing and implementing an intravenous therapy book. The pharmacological effects of novel nutrients on the immune system
  • Abstracts: Mortgaging our future-The cost of medical education. Trends in embryo-transfer practice and in outcomes of the use of assisted reproduuctive technology in the united states
  • Abstracts: Benzodiazepine use and the risk of motor vehicle crash in the elderly. Essential nutrients: Food or supplements?
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.